The study investigated the mechanism of the interaction between valproate and carbamazepine which causes raised plasma carbamazepine-10,11-epoxide concentrations with unchanged plasma carbamazepine concentrations. This interaction has usually been attributed to valproate inhibiting epoxide hydrolase, the enzyme that catalyses the biotransformation of carbamazepine-10,11-epoxide to carbamazepine-10,11-trans-diol. Methods Clearances of plasma carbamazepine, carbamazepine-epoxide and carbamazepine-diol to relevant carbamazepine metabolites present in urine were measured under steady-state conditions in 17 adults receiving carbamazepine as anticonvulsant monotherapy, and in 10 adults taking the drug together with valproate. Results Plasma carbamazepine-epoxide concentrations were higher, relative to carbamazepine dose, in the co-medicated patients. Plasma apparent clearances of carbamazepine, relative to drug dose, were similar whether or not valproate was taken. Formation clearances of carbamazepine-10,11-trans-diol conjugate, and probably of carbamazepine-10,11-trans-diol, were lower in subjects co-medicated with valproate, and a higher proportion of the carbamazepine dose was excreted in urine as carbamazepine-10,11-epoxide. Conclusions Valproate appears to inhibit the glucuronidation of carbamazepine-10,11-trans-diol, and probably also inhibits the conversion of carbamazepine-10,11-epoxide to this trans-diol derivative, rather than simply inhibiting the latter reaction only.
Introduction Methods
Administration of the anticonvulsant valproate (VPA) to Subjects patients taking carbamazepine (CBZ) is associated with a rise in the plasma concentration of the CBZ metabolite
The study was carried out in two groups of informed consenting adult epileptic patients, 17 receiving carbamazecarbamazepine-10,11-epoxide (CBZ-epoxide) without any appreciable change in the plasma concentration of CBZ pine alone (the CBZ group) and 10 receiving it with sodium valproate (the VPA-CBZ group). The characteristics itself [1] [2] [3] [4] [5] . This interaction may go unrecognised if plasma concentrations of CBZ alone are monitored. However, it of the 17 patients in the CBZ group have been described in another publication dealing with the mechanism of the may have clinical consequences, since CBZ-epoxide is a reasonably potent anticonvulsant and sedative in its own dose-dependent clearance of CBZ [7] . The characteristics of the 10 VPA-CBZ comedicated patients are shown in right. The usually accepted mechanism of the interaction is inhibition of CBZ-epoxide conversion to carba- Table 1 . The CBZ group comprised 4 males and 13 females, and the VPA-CBZ group 5 males and 5 females (% male mazepine-10,11-trans-diol (CBZ-diol ) [6] . This reaction is catalysed by microsomal epoxide hydrolase. However, 23 .5% vs 50%: difference=−26.5%595% C.I.=−63.4% to 10.5%). The mean ages of subjects were: CBZ group certain published clinical and biochemical data are not entirely consistent with this belief. We have therefore 60.6±s.d. 9.8 years; VPA-CBZ group 40.9±15.8 years (difference=19.7 years; 95% C.I.=9.6 to 29.9 years). attempted to determine the mechanism of the interaction in humans under therapeutic conditions, by studying steady-
The mean daily CBZ doses in the two groups were reasonably similar: 9.22±s.d. Plasma concentration: dose relationships measured in urine: CBZ, CBZ-epoxide, CBZ-diol, CBZacridan, 2-hydroxy-CBZ (2-OH-CBZ) and 3-hydroxy-
The equations for the linear regressions for plasma concentration of (i) CBZ (ii) CBZ-epoxide (iii) unconjugated CBZ (3-OH-CBZ). Except for CBZ and CBZ-epoxide, all the above substances were measured both before and after CBZ-diol and (iv) conjugated CBZ-diol, on carbamazepine daily dose per unit body weight, for the CBZ and the VPAhydrolysis with b-glucuronidase (from Helix pomatia, type H-2, Sigma Chemical Co., St Louis, MO). Thus each CBZ groups, are shown in Table 2 . There was a statistically significant difference between the groups only for one pair unconjugated metabolite was measured directly, and its conjugated counterpart was measured by subtracting the of regressions, that for plasma CBZ-epoxide concentration on CBZ dose. The plasma CBZ-epoxide concentrations value for the unconjugated metabolite from that for the corresponding total metabolite. tended to be higher, relative to drug dose, in the patients comedicated with VPA, whereas the plasma concentrations The h.p.l.c. assay methods used have been described previously [7, 8] . The intra-assay variability was ≤4% and of CBZ, and unconjugated and conjugated CBZ-diol, relative to CBZ dose, did not differ between the two sets the inter-assay variability ≤6% for CBZ, CBZ-epoxide, CBZ-acridan, 2-OH-CBZ and 3-OH-CBZ at concenof subjects. This confirmed the existence of the previously described CBZ-VPA interaction, which yields increased trations of 2, 10 and 40 mg l 
Plasma CBZ apparent clearance (CL/F) Data analysis
Steady-state clearances were calculated as follows: for CBZ The plasma apparent clearance (CL/F ) of CBZ is dosedependent [7] . Regressions for CL/F on CBZ dose did not itself, CL/F as oral dose per day/mid-interval plasma concentration; for formation of each of the various differ significantly between the CBZ group (CL/F= 35.20±6.265 CBZ dose/wt; mean value=92.8±33.1 1 metabolites studied, sum of the amount(s) of that metabolite and all measured substances derived from it excreted in day 
metabolites. Therefore the regressions for formation clearMetabolite excretions in urine
ance on CBZ dose for CBZ-epoxide and CBZ-diol were compared for the CBZ group and the CBZ-VPA group The mean percentages of the CBZ dose recovered in urine as parent substance plus derived metabolites were very ( Figure 1b and 1c, where the regression equations are shown in the legend and, purely for comparison, similar data are similar for the CBZ group and the VPA-CBZ group (48.6±14.8% and 46.4±11.3% respectively: difference shown for CBZ-diol conjugate- Figure 1d ). With the outlier excluded, the regressions for CBZ-epoxide formation 2.2%; 95% CI=−9.0% to 13.4%).
Percentages of the CBZ dose excreted in urine as the clearance did not differ between the two Groups (slopes: F=0.7623; df=1,22; P=0.392: line separations: F=0.1831; various metabolites studied in the two patient groups are shown in Table 3 . The only statistically significant differences df=1,23; P=0.623). The regressions for CBZ-diol formation clearance did differ (slopes: F=3.498; df=1,22; P= between the groups were: (i) a higher mean percentage of the CBZ dose was excreted as CBZ-epoxide in the CBZ-0.075: line separation: F=4.541; df=1,23; P=0.044). Thus in subjects co-medicated with VPA, the regression analysis VPA subjects (1.59% vs 1.07%) and (ii) a lower mean percentage of the dose was excreted as CBZ-diol conjugate suggested a statistically significantly lower formation clearance of CBZ-diol. A lower formation clearance of CBZin this group (7.13% vs 9.78%).
diol conjugate had also been found, so that two consecutive stages in the epoxide-diol pathway appeared to be inhibited Formation clearances of CBZ metabolites by VPA. The calculated values of the formation clearances of the various CBZ metabolites studied in the CBZ group and the Discussion CBZ-VPA group are compared in Table 4 , where the comparisons are also shown after exclusion of one outlying It is generally accepted that biological oxidation of CBZ to its epoxide, followed successively by hydration of CBZsubject, who had a very aberrant CBZ-diol conjugate formation clearance. There were no statistically significant epoxide to CBZ-diol, and then conjugation of the diol with glucuronic acid, comprises the main metabolic pathway of differences in mean formation clearance for any metabolite before exclusion of the outlier: after exclusion, mean the drug in humans [9] . Recognition of the existence of the valproate-carbamazepine interaction has usually depended formation clearance of CBZ-diol conjugate was statistically significantly lower in the CBZ-VPA group (17.58±4.80 vs on simultaneous measurement of plasma CBZ and CBZepoxide concentrations. These measurements have repeat-24.14±5.81 l day −1 ).
Steady-state plasma apparent clearance of CBZ is known edly shown higher plasma levels of the epoxide in the presence of relatively unchanged levels of the parent drug to be dose-dependent [7] . Hence some of the formation clearances of CBZ metabolites might also be dose-dependent.
i.e. raised CBZ-epoxide/CBZ ratios, when CBZ and VPA are taken together [1, [10] [11] [12] [13] [14] . Inhibition of microsomal This proved to be the case for the formation clearances of CBZ-epoxide and CBZ-diol, but not for those of the other epoxide hydrolase activity would suffice to account for this finding, though it is not the only theoretical possibility. ditions in humans, this group of workers obtained evidence that valproate intake led to a decreased formation clearance Published attempts to define the mechanisms of the interaction experimentally have led to somewhat ambiguous of CBZ-diol [5] . Pisani et al.
[15] found a decreased plasma clearance of a single dose of CBZ-epoxide given to persons outcomes. Thus, in humans, Levy et al. [10] found valproate comedication caused a fall in plasma carbamazepine concentaking valproate, consistent with decreased microsomal epoxide hydrolase activity or a decrease in metabolism tration, but they gave VPA for only 6 days, which may not have been long enough for a new CBZ steady state to further along the epoxide-diol pathway. Mattson et al. [16] showed that VPA reduced the plasma protein binding of develop. Subsequently, under probable steady-state con- CBZ, in vitro. In monkeys, Levy et al. [10] showed that gation had become disinhibited after VPA was no longer present, and was more suggestive of decreased activation of VPA decreased the plasma protein binding of both CBZ and its epoxide, and decreased the elimination clearance of CBZ oxidation. Omtzigt et al. [21] found that, in pregnant women, VPA co-medication led to lowered plasma CBZ CBZ-epoxide, again consistent with decreased epoxide hydrolase activity (or with decreased glucuronidation of levels, slightly raised CBZ-epoxide levels and to a decreased proportion of the CBZ dose being excreted in urine as CBZ-diol ). Subsequently Chang & Levy [17, 18] in the isolated perfused rat liver found that VPA decreased the CBZ-diol (unconjugated plus conjugated). While pregnancy itself is known to alter CBZ metabolism [8] , this finding formation clearance of CBZ-epoxide and the intrinsic clearances of CBZ, but also the clearance of CBZ-epoxide, was not consistent with microsomal epoxide hydrolase inhibition as the sole metabolic alteration present in the again consistent with inhibition of epoxide hydrolase or of diol glucuronidation. However, the in vitro biochemical valproate comedicated subjects. Svinarov & Pippenger [22] measured plasma (unconjugated) CBZ-diol levels as well as studies of Pacifici et al. [19] failed to show inhibition of epoxide hydrolase activity by CBZ, a finding which deterred simultaneous CBZ and CBZ-epoxide levels. In those taking VPA plus CBZ there were raised plasma levels of CBZ and acceptance of the hypothesis that VPA raised plasma CBZepoxide concentrations by inhibiting the enzyme responsible of both of its metabolites (though CBZ levels were increased only in children). On this basis they concluded that VPA for its further metabolism. Later Kerr et al. [5] showed that VPA (at 100 mm, but not at the more therapeutically relevant was a general inhibitor of the epoxide-diol pathway, and not purely an inhibitor of the epoxide hydrolase catalysed concentration of 10 mm) did inhibit microsomal epoxide hydrolase. Since the publication of this result the mechanism stage. The studies described in the present paper have gone of the interaction seems to have been generally accepted, at least tacitly, to be microsomal epoxide hydrolase inhibition.
further than previous published work in humans, by measuring not only the plasma concentrations of all known However, discordant observations continued to appear. Thus Miller et al. [20] noted that, unexpectedly, CBZ clearance metabolites on the epoxide-diol pathway, but the simultaneous urinary excretions of these metabolites and also the fell in humans when VPA was withdrawn from CBZ-VPA combination therapy. This should not have occurred if excretions of the drug's acridan and phenolic metabolites. The studies also related the clearances to the CBZ dose, microsomal epoxide hydrolase activity or CBZ-diol conju-carbamazepine epoxide levels by comedication with valproate where some of the clearances proved to be dose dependent. proportion of the CBZ dose excreted into urine as CBZ-
